Available Technologies
# of Displayed Technologies: 10 / 29
Applied Category Filter (Click To Remove): Small Molecules
Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings.
The Need
The rise of these resilient multi-drug resistant bacteria has …
- College: College of Medicine (COM)
- Inventors: Pancholi, Vijay
- Licensing Officer: Schultz, Teri
Protecting the vascular endothelial barrier – a novel approach to treating atrial fibrillation
TS-063433 — A new pharmacologic modality for treating AFib.
Atrial fibrillation (AF) is the most common form of irregular cardiac rhythm (arrhythmia), affecting approximately 3% of the US population. It is a significant risk factor for heart failure, ischemic stroke, and sudden cardiac death. The AF mortality rate is growing globally, and risk factors known …
- College: College of Engineering (COE)
- Inventors: Veeraraghavan, Rengasayee; Mezache, Louisa
- Licensing Officer: Schultz, Teri
Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: OSU Wexner Medical Center
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: College of Pharmacy
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need:
Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
- Licensing Officer: Schworer, Adam
Addressing the Treatment Gap in Advanced Liposarcoma
TS-062480 — Novel therapeutic compounds to treat advanced liposarcoma.
Patients diagnosed with advanced liposarcoma (LPS) face a significant treatment challenge, as current chemotherapy approaches exhibit low response rates of only 25%, leading to a dismal overall survival at 5 years, ranging between 20% to 34%.
The Need
Despite extensive efforts, there has been no s…
- College: College of Medicine (COM)
- Inventors: Beane, Joal; Goryunova, Marina; Hadad, Christopher; He, Yiran; Zhu, Hua
- Licensing Officer: Schultz, Teri
Novel use of novobiocin to potentiate the antimicrobial efficacy of polymyxins
TS-062439 — The Need: Addressing the Growing Threat of Gram-Negative Bacterial Infections
Gram-negative bacterial pathogens, including Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae, are responsible for more than 35% of common hospital-acquired infections. These no…
- College: College of Arts & Sciences
- Inventors: Kahne, Daniel; Baidin, Vadim; Mandler, Michael; Ruiz, Natividad
- Licensing Officer: Willson, Christopher
Unleashing the Power of Radiotherapy - Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.
Papaverine is an FDA-approved potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been shown to be responsible for increased oxygenation and enhanced radiation response. However, papaverine is also a phosphodiesterase 10A (PDE10A) inhibitor and its…
- College: College of Medicine (COM)
- Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
- Licensing Officer: Schultz, Teri
FraB as a drug target and FraB inhibitors as Salmonella-specific narrow-spectrum therapeutics
TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics of salmonellosis, as well as small molecule inhibitors of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy of FraB inhibitors.
Non-typhoidal salmonellosis is one of the most significant food-borne diseases, in the United States and globally. There are no vaccines available for human use to prevent this disease, and only broad-spectrum antibiotics available to treat the disease. However, antibiotic resistance is on the ris…
- College: College of Medicine (COM)
- Inventors: Ahmer, Brian; Boulanger, Erin; Cool, Austin; Gopalan, Venkat; Kovvali, Sai Sravya Varali; Law, Jamison; Lindert, Steffen; Sabag-Daigle, Anice; Sengupta, Anindita; Thirugnanasambantham, Pankajavalli
- Licensing Officer: Schultz, Teri
An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 —
A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
- College: College of Medicine (COM)
- Inventors: Bansal, Shyam; Gumina, Richard
- Licensing Officer: He, Panqing
